Unknown PHASE4 INTERVENTIONAL 2-arm NCT03270007

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Sponsor: Tao OUYANG

Interventions Vinorelbine

Updated 7 times since 2017 Last updated: Oct 26, 2020 Started: Nov 10, 2017 Primary completion: Jun 30, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Primary Breast Cancer, this trial is ongoing. The trial is conducted by Tao OUYANG and has accumulated 7 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE4
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Feb 2019 — Nov 2020 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Sep 2017 — Feb 2019 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tao OUYANG

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China